CLINICAL_TRIALS
ClinicalTrials.gov record update
Predictive Impact of Peripheral Blood Lymphocytes on clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT06805812
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:26:54.000647+00:00
- Published At
- 2025-02-03T00:00:00+00:00
- Record Updated At
- 2025-02-03
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Breast Adenocarcinoma", "Breast Cancer Stage IV", "Breast Cancer, Metastatic", "Breast Carcinoma", "Breast Diseases", "Breast Neoplasms", "Breast Neoplasms, Male", "Breast Cancer", "Breast Cancer With Metastatic Bone Disease", "Breast Cancers", "Breast Neoplasm", "Breast Tumors", "HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer", "HR+ Advanced or Metastatic Breast Cancer", "HR+/HER2- Breast Cancer", "HRpos Breast Neoplasms", "HR-positive, HER2-negative Advanced Breast Cancer", "HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer", "HR-positive Breast Cancer", "Hormone Receptor-Positive Breast Cancer", "Hormone Receptor Positive Breast Adenocarcinoma", "Hormone Receptor Positive Breast Carcinoma", "Hormone Receptor Positive Breast Neoplasms", "Hormone Receptor Positive HER-2 Negative Breast Cancer", "Hormone Receptor Positive Malignant Neoplasm of Breast", "Hormone Receptor Positive Metastatic Breast Cancer", "Hormone Receptor Positive, HER2 Negative Breast Cancer", "Hormone Receptor Negative Breast Cancer", "Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer", "Hormone Receptor Positive Breast Cancer", "Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer", "Hormone Receptor Positive, HER2-negative Neoplasms", "Hormone Receptor Positive, HER2-low Neoplasms", "Hormone Receptor Positive (HR+), HER2-negative Breast Cancer", "Hormone Receptor (HR)-Positive Breast Cancer", "Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer", "Palbociclib", "Ribociclib", "Abemaciclib", "CDK4/6 Inhibitor", "CDK4/6 Inhibitors"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-02-03"- protocolSection.identificationModule.nctId
"NCT06805812"- protocolSection.identificationModule.officialTitle
"Predictive Impact of Peripheral Blood Lymphocytes on clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study"- protocolSection.statusModule.overallStatus
"RECRUITING"- protocolSection.designModule.phases
[]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.